The Conversation (0)
April 29, 2025
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.
22 December 2025
Hanlim & Korean Government Fund Pathway to Clinical Trial
Invion Limited (IVX:AU) has announced Hanlim & Korean Government Fund Pathway to Clinical TrialDownload the PDF here. Keep Reading...
02 December 2025
Invion Secures Expanded Photosoft Global Exclusive License
Invion Limited (IVX:AU) has announced Invion Secures Expanded Photosoft Global Exclusive LicenseDownload the PDF here. Keep Reading...
30 October 2025
Appendix 4C and Quarterly Activities Report - September 2025
Invion Limited (IVX:AU) has announced Appendix 4C and Quarterly Activities Report - September 2025Download the PDF here. Keep Reading...
20 October 2025
Funded Collaboration Agreement with Protect Animal Health
Invion Limited (IVX:AU) has announced Funded Collaboration Agreement with Protect Animal HealthDownload the PDF here. Keep Reading...
09 October 2025
Repayment of Lind Facility with Successful Capital Raise
Invion Limited (IVX:AU) has announced Repayment of Lind Facility with Successful Capital RaiseDownload the PDF here. Keep Reading...
22h
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule
KELOWNA, BC / ACCESS Newswire / October 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has been reached and dosing continues on schedule with Human Pilot Study #7 (GLP-1-H26-7) which is... Keep Reading...
15 October
Lexaria Announces Results From Animal Study GLP-1-A26-1
(TheNewswire) Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD Kelowna, BC October 15, 2026 TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following... Keep Reading...
15 October
Lexaria Announces Results from Animal Study GLP-1-A26-1
KELOWNA, BC / ACCESS Newswire / October 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following results from animal study GLP-1-A26-1 (the "Study") that evaluated a number of formulation... Keep Reading...
06 October
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
KELOWNA, BC / ACCESS Newswire / October 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is providing this strategic update.Lexaria's DehydraTECHâ„¢ technology is currently being evaluated both by Lexaria and... Keep Reading...
02 October
BriaCell’s Bria-ABC Joins Roster of US-Enrolled Breast Cancer Trials
BriaCell Therapeutics’ (TSX:BCT,NASDAQ:BCTX) Phase 3 Bria-ABC study has been included in a roundup of breast cancer clinical trials currently enrolling in the US, published by cancer publication CURE.In its September 24 article, CURE enumerated seven studies spanning early-stage to heavily... Keep Reading...
17 September
Lexaria Updates Financial Position
KELOWNA, BC / ACCESS Newswire / September 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following update.Lexaria is in a strong cash position following both its recently announced Australian tax... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00